Literature DB >> 8203841

Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection.

S P Bonacorsi1, M R Scavizzi, A Guiyoule, J H Amouroux, E Carniel.   

Abstract

Amoxicillin, cefotaxime, ceftriaxone, gentamicin, doxycycline, and ofloxacin were active in vitro, like the reference drug streptomycin, against the virulent strain Yersinia pestis 6/69M. The comparative efficacies of these drugs in vivo were evaluated in a standardized and reproducible mouse model of systemic infection. Each antibiotic was injected intravenously once, at 24 h postinfection, and then repeatedly during 48 h. In vivo results were measured by counting the viable bacteria recovered from the whole spleens of mice sacrificed at selected times. All the drugs were manifestly successful; ceftriaxone, ofloxacine, and the reference drug were the most effective. Therefore, gentamicin and doxycycline could be used, depending on the clinical forms of the Y. pestis infection. Further investigations on beta-lactams, especially those used in the present study, could be carried out to confirm or not confirm their activities against Y. pestis. Ofloxacin appeared to be as active and to perform as rapidly as streptomycin in the treatment of murine Y. pestis infection, which is in agreement with the previous successes obtained with the use of fluoroquinolones in the treatment of murine infections caused by other pathogenic yersiniae.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8203841      PMCID: PMC284484          DOI: 10.1128/AAC.38.3.481

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Studies on immunization against plague. V. Multiplication and persistence of virulent and avirulent Pasteurella pestis in mice and guinea pigs.

Authors:  D L WALKER; L E FOSTER; T H CHEN; A LARSON; K F MEYER
Journal:  J Immunol       Date:  1953-03       Impact factor: 5.422

2.  Chromosomal marker for the 'high pathogenicity' phenotype in Yersinia.

Authors:  E Carniel; A Guiyoule; O Mercereau-Puijalon; H H Mollaret
Journal:  Contrib Microbiol Immunol       Date:  1991

3.  Modern therapy of plague.

Authors:  K F MEYER
Journal:  J Am Med Assoc       Date:  1950-11-18

4.  The possible role of quinolones in yersiniosis.

Authors:  J A Hoogkamp-Korstanje
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  "In vitro" sensitivity of 100 strains of Pasteurella pestis from Northeastern Brazil to antibiotics and a compound sulphonamides.

Authors:  D A Mello
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1970 May-Jun       Impact factor: 1.846

6.  Antibiotic treatment of Yersinia enterocolitica septicemia: a retrospective review of 43 cases.

Authors:  M Gayraud; M R Scavizzi; H H Mollaret; L Guillevin; M J Hornstein
Journal:  Clin Infect Dis       Date:  1993-09       Impact factor: 9.079

7.  Failure of newer beta-lactam antibiotics for murine Yersinia enterocolitica infection.

Authors:  M R Scavizzi; J M Alonso; A M Philippon; A M Jupeau-Vessieres; A Guiyoule
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

8.  Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins.

Authors:  N Frimodt-Møller; M W Bentzon; V F Thomsen
Journal:  J Infect Dis       Date:  1986-09       Impact factor: 5.226

9.  Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics.

Authors:  A U Gerber; H P Brugger; C Feller; T Stritzko; B Stalder
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

10.  In vitro susceptibilities of 126 clinical isolates of Yersinia enterocolitica to 21 beta-lactam antibiotics.

Authors:  M J Hornstein; A M Jupeau; M R Scavizzi; A M Philippon; P A Grimont
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

View more
  21 in total

Review 1.  Use of aminoglycosides in treatment of infections due to intracellular bacteria.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 2.  Resistance of Yersinia pestis to antimicrobial agents.

Authors:  Marc Galimand; Elisabeth Carniel; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

3.  Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model.

Authors:  Arnold Louie; Brian Vanscoy; Weiguo Liu; Robert Kulawy; David Brown; Henry S Heine; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-04-12       Impact factor: 5.191

4.  High-throughput, signature-tagged mutagenic approach to identify novel virulence factors of Yersinia pestis CO92 in a mouse model of infection.

Authors:  Duraisamy Ponnusamy; Eric C Fitts; Jian Sha; Tatiana E Erova; Elena V Kozlova; Michelle L Kirtley; Bethany L Tiner; Jourdan A Andersson; Ashok K Chopra
Journal:  Infect Immun       Date:  2015-03-09       Impact factor: 3.441

5.  Identification and characterization of the hemophore-dependent heme acquisition system of Yersinia pestis.

Authors:  M S Rossi; J D Fetherston; S Létoffé; E Carniel; R D Perry; J M Ghigo
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  Plague--clinical features and management.

Authors:  S K Kabra; Y Jain; V Seth
Journal:  Indian J Pediatr       Date:  1994 Nov-Dec       Impact factor: 1.967

7.  In vitro antimicrobial susceptibilities of strains of Yersinia pestis.

Authors:  M D Smith; D X Vinh; T T Nguyen; J Wain; D Thung; N J White
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

8.  Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.

Authors:  A Louie; H S Heine; B VanScoy; A Eichas; K Files; S Fikes; D L Brown; W Liu; M Kinzig-Schippers; F Sörgel; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

9.  Antibiotic treatment of experimental pneumonic plague in mice.

Authors:  W R Byrne; S L Welkos; M L Pitt; K J Davis; R P Brueckner; J W Ezzell; G O Nelson; J R Vaccaro; L C Battersby; A M Friedlander
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

10.  Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections.

Authors:  J L Fournier; F Ramisse; A C Jacolot; M Szatanik; O J Petitjean; J M Alonso; M R Scavizzi
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.